Articles related to ACUTE CORONARY SYNDROME (ACS)

“The idea of preserving and reducing thrombosis without increasing bleeding is very, very exciting.” — Roxana Mehran, MD, SCAI 2025

Patients with ACS are at the highest risk for cardiovascular complications both acutely and chronically, which emphasizes the importance of staying up-to-date on the most recent evidence presented in this guideline.

Research shows that women account for 50% of MINOCA cases but only 25% of myocardial infarctions due to obstructive coronary artery disease, highlighting the importance of considering this diagnosis in female patients presenting with MI symptoms.

Multiple post-licensure studies have failed to demonstrate ticagrelor’s superiority over clopidogrel, prompting leading cardiologists to call for guideline reappraisal.

In a comprehensive Bayesian network meta-analysis, 1 month of DAPT followed by potent P2Y12 inhibitor monotherapy was associated with a significant reduction in major bleeding compared to the conventional 12 months of DAPT, without an increase in MACCE.

In patients with chronic kidney disease, the elevated troponin challenge necessitates a nuanced approach, integrating serial measurements and clinical context to discern acute coronary syndrome from chronic elevations, thereby informing targeted management strategies.